Inovio Pharma (INO)
$8.81
0.07 (0.80%)
INO Stock Quote Delayed 30 Minutes
Sell Inovio While You Still Can
INO stock is poised to fall further as the chances of a vaccine approval fall and its competitors widen their lead
Louis Navellier's Top 6 Stocks for 2021
He found Apple at $1.49… Intel at $3.60... Amazon at $46. Now, investing legend Louis Navellier is revealing his Top 6 Stocks for 2021 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.83B
PE Ratio
-4.14
EPS
-2.13
Volume (Avg. Vol.)
6.25M
Day's Range
8.59 - 8.96
52-Week Range
8.06 - 33.79
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
Just Say No to Inovio Pharmaceuticals Stock
While INO stock has boasted a banner year, Inovio appears no closer to a Covid-19 vaccine than any of the other 150 contenders.
Count on the Advancement of DNA Medicine with Inovio Stock
If you're thinking that INO stock is just a wager on a Covid-19 vaccine candidate, think again. Inovio's pipeline is robust and diverse.
Prepare for Phase 2 and a Comeback for Inovio
Is INO stock nothing more than a post-pandemic pop-and-drop story? Don't count Inovio out as a crucial funding source offers timely support.
Inovio Gets the Go-Ahead But It’s Probably Too Late
Inovio got the go-ahead from the FDA on Nov. 16 to resume its Phase 2 clinical trial. Is INO stock worth betting on this late in the game?
Inovio Pharmaceutical’s FDA Plight Makes It a Highly Risky Bet
INO stock has tumbled in the past few months. Inovio needs the FDA to bail it out by allowing the advanced trials of its vaccine to begin.
The Clock Is Ticking for Inovio Stock
The FDA recently lifted the clinical hold on Inovio's Covid-19 vaccine candidate. The result could mean huge returns for INO stock.
Inovio Has Little to Show for Its Covid-19 Efforts
Inovio Pharmaceuticals has little to show for its Covid-19 efforts. INO stock is not worth more than $2, according to one short-seller.
At This Point, Go Ahead and Count Inovio Pharmaceuticals Out of the Vaccine Race
INO stock is a purely speculative bet. I don't see the company being among the few that deliver a vaccine against Covid-19.
Can Inovio Benefit From All Of Its Vaccine Delays?
Shares of Inovio (NASDAQ:INO) are trading near a six-month low. The company is being battered by delays in getting its Covid-19 vaccine candidate into Phase....
Avoid Taking a Bet on the Deep Correction In Inovio Stock
Small-cap biotechs are inherently challenging. With a failed INO-4800 timeline, INO stock increasingly finds itself back in this group.
Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials
While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.
Inovio Investors Need FDA to Write Positive Prescription for Stock Gains
The bad news is that the FDA recently halted the Inovio trial. Think about that for a moment. The world is in dire of need of a Covid-19 vaccine and the U.S. is engaged “Operation Warp Speed” to get a vaccine to market, but here's a regulator telling Inovio to pump the brakes.
The FDA’s Questions Aren’t a Deal Breaker for Inovio Stock
INO stock is down but not out as the development of a Covid-19 vaccine is bound to have some bumps in the road.
Could the FDA Be Ready to Crash Inovio’s Hopes and Dreams?
It’s been a month since the FDA put Inovio’s Covid-19 vaccine on partial clinical hold. No news is definitely not good news for INO stock.
Time Is Running Out on Inovio as Other Vaccine Candidates Advance
The FDA's latest decision has dealt a killer blow to INO stock, which was already struggling to keep up with Big Pharma in the vaccine race.
Investors Should Buy the Phase II/III Dip in Inovio
INO stock is in a rough spot of late, but it is poised to bounce back from these temporary setbacks with a strong product portfolio.
Why the FDA’s Inquiry of Inovio Is More Critical Than You Think
INO stock tumbled due to the FDA asking questions about the underlying DNA vaccine. Here’s why you should be concerned.
Avoid Inovio Like the Plague After Its 64% Price Drop
INO stock has fallen more than 60% since June and further declines look imminent as the company struggles with its Covid-19 vaccine.
